Differential expression of histone post-translational modifications in acute myeloid and chronic lymphocytic leukemia determined by high-pressure liquid chromatography and mass spectrometry

Journal of the American Society for Mass Spectrometry

Volumn 15, Issue 1, 2004, Pages 77-86

  Zhang, Liwen ^a   Freitas, Michael A ^a   Wickham, Joseph ^a   Parthun, Mark R ^a   Klisovic, Marko I ^a   Marcucci, Guido ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELLS; ENZYME INHIBITION; HIGH PRESSURE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR STRUCTURE; PATIENT TREATMENT; TUMORS;

IMMUNOASSAY TECHNIQUES; POST-TRANSLATIONAL MODIFICATIONS;

PROTEINS;

DEPSIPEPTIDE; HISTONE; HISTONE DEACETYLASE INHIBITOR;

LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONCENTRATION RESPONSE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MASS SPECTROMETRY; PROTEIN PROCESSING; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY AND SPECIFICITY; THYMUS; VALIDATION PROCESS;

BOVINAE;

EID: 0347123341     PISSN: 10440305     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jasms.2003.10.001     Document Type: Article

References (47)

1. Annunziato A.T., Hansen J.C. Role of Histone Acetylation in the Assembly and Modulation of Chromatin Structures. Gene Exp. 9:2000;37-61.
2. Johnson C.A., Turner B.M. Histone Deacetylases Complex Transducers of Nuclear Signals . Semin. Cell Dev. Biol. 10:1999;179-188.
3. Berger S.L. Histone Modifications in Transcriptional Regulation. Curr. Opin. Genet. Dev. 12:2002;142-148.
4. Howe L., Brown C.E., Lechner T., Workman J.L. Histone Acetyltransferase Complexes and Their Link to Transcription. Crit. Rev. Eukaryot. Gene Exp. 9:1999;231-243.
5. Stallcup M.R. Role of Protein Methylation in Chromatin Remodeling and Transcriptional Regulation. Oncogene. 20:2001;3014-3020.
6. van Leeuwen F., Gafken P.R., Gottschling D.E. Dot1p Modulates Silencing in Yeast by Methylation of the Nucleosome Core. Cell. 109:2002;745-756.
7. Ng H.H., Feng Q., Wang H., Erdjument-Bromage H., Tempst P., Zhang Y., Struhl K. Lysine Methylation Within the Globular Domain of Histone H3 by Dot1 is Important for Telomeric Silencing and Sir Protein Association. Genes Dev. 16:2002;1518-1527.
8. Briggs S.D., Xiao T., Sun Z.-W., Caldwell J.A., Shabanowitz J., Hunt D.F., Allis C.D., Strahl B.D. Gene Silencing Trans-Histone Regulatory Pathway in Chromatin . Nature (London). 418:2002;498.
9. Crane-Robinson C., Hebbes T.R., Clayton A.L., Thorne A.W. Chromosomal Mapping of Core Histone Acetylation by Immunoselection. Methods. 12:1997;48-56.
10. Suka N., Suka Y., Carmen A.A., Wu J., Grunstein M. Highly Specific Antibodies Determine Histone Acetylation Site Usage in Yeast Heterochromatin and Euchromatin. Mol. Cell. 8:2001;473-479.
11. Lo W.-S., Trievel R.C., Rojas J.R., Duggan L., Hsu J.-Y., Allis C.D., Marmorstein R., Berger S.L. Phosphorylation of Serine 10 in Histone H3 is Functionally Linked in Vitro and in Vivo to Gcn5-Mediated Acetylation at Lysine 14. Mol. Cell. 5:2000;917-926.
12. Edmondson D.G., Davie J.K., Zhou J., Mirnikjoo B., Tatchell K., Dent S.Y.R. Site-Specific Loss of Acetylation Upon Phosphorylation of Histone H3. J. Biol. Chem. 277:2002;29496-29502.
13. Ho Y.-P., Hsu P.-H. Investigating the Effects of Protein Patterns on Microorganism Identification by High-Performance Liquid Chromatography-Mass Spectrometry and Protein Database Searches. J. Chromatogr. A. 976:2002;103-111.
14. Bischoff R. Characterization of Proteins, Peptides, and Polynucleotides by Mass Spectrometry. Gooding K.M., Regnier F. 2nd ed HPLC of Biological Macromolecules. Vol. LXXXVII:2002;689-738 Marcel Dekker, Inc, New York.
15. Ostrowski L.E., Blackburn K., Radde K.M., Moyer M.B., Schlatzer D.M., Moseley A., Boucher R.C. A Proteomic Analysis of Human Cilia Identification of Novel Components . Mol. Cell. Proteom. 1:2002;451-465.
16. Sures I., Gallwitz D. Histone-Specific Acetyltransferases from Calf Thymus. Isolation, Properties, and Substrate Specificity of Three Different Enzymes. Biochemistry. 19:1980;943-951.
17. Cheson B.D., Bennett J.M., Grever M., Kay N., Keating M.J., Obrien S., Rai K.R. National Cancer Institute-Sponsored Working Group Guidelines for Chronic Lymphocytic Leukemia Revised Guidelines for Diagnosis and Treatment . Blood. 87:1996;4990-4997.
18. Weitkamp J.H., Crowe J.E. Blood Donor Leukocyte Reduction Filters as a Source of Human B Lymphocytes. Biotechniques. 31:2001;464.
19. Aron J.L., Parthun M.R., Marcucci G., Kitada S., Mone A.P., Davis M.E., Shen T., Murphy T., Wickham J., Kanakry C., Lucas D.M., Reed J.C., Grever M.R., Byrd J.C. Depsipeptide (FR901228) Induces Histone Acetylation and Inhibition of Histone Deacetylase in Chronic Lymphocytic Leukemia Cells Concurrent with Activation of Caspase-8-Mediated Apoptosis and Downregulation of c-FLIP Protein. Blood. 102:2003;652-658.
20. Galasinski S.C., Louie D.F., Gloor K.K., Resing K.A., Ahn N.G. Global Regulation of Post-Translational Modifications on Core Histones. J. Biol. Chem. 277:2002;2579-2588.
21. Marks P.A., Richon V.M., Rifkind R.A. Histone Deacetylase Inhibitors Inducers of Differentiation or Apoptosis of Transformed Cells . J. Natl. Cancer Inst. 92:2000;1210-1216.
22. Marks P.A., Rifkind R.A., Richon V.M., Breslow R. Inhibitors of Histone Deacetylase are Potentially Effective Anticancer Agents. Clin. Cancer Res. 7:2001;759-760.
23. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone Deacetylases and Cancer Causes and Therapies . Nat. Rev. Cancer. 1:2001;194-202.
24. Marks P.A., Richon V.M., Breslow R., Rifkind R.A. Histone Deacetylase Inhibitors as New Cancer Drugs. Curr. Opin. Oncol. 13:2001;477-483.
25. Melnick A., Licht J.D. Histone Deacetylases as Therapeutic Targets in Hematologic Malignancies. Curr. Opin. Hematol. 9:2002;322-332.
26. Johnstone R.W. Histone-Deacetylase Inhibitors Novel Drugs for the Treatment of Cancer . Nat. Rev. Drug Discov. 1:2002;287-299.
27. Jung M. Inhibitors of Histone Deacetylase as New Anticancer Agents. Curr. Med. Chem. 8:2001;1505-1511.
28. Grozinger C.M., Schreiber S.L. Deacetylase Enzymes Biological Functions and the Use of Small-Molecule Inhibitors . Chem. Biol. 9:2002;3-16.
29. Asou H., Tashiro S., Hamamoto K., Otsuji A., Kita K., Kamada N. Establishment of a Human Acute Myeloid Leukemia Cell Line (Kasumi-1) with 8;21 Chromosome Translocation. Blood. 77:1991;2031-2036.
30. Klisovic M., Maghraby E.A., Murphy T., Sklenar A.R., Parthun M.R., Aron J., Guimon M., Sklenar A., Archer K., Whitman S., Rush L., Plass C., Grever M.G., Byrd J.C., Marcucci G. Depsipeptide (FR901228) Promotes Histone Acetylation, Gene Transcription, Apoptosis, and Synergizes with DNA Methyltransferase Inhibitors in AML1-ETO-Positive Leukemic Cells A Potential Therapeutic Strategy for Histone Deacetylase-Driven Leukemogenesis . Leukemia. 17:2003;350-358.
31. Meyers S., Downing J.R., Hiebert S.W. Identification of AML-1 and the (8;21) Translocation Protein (AML-1/ETO) as Sequence-Specific DNA-Binding Proteins The Runt Homology Domain is Required for DNA Binding and Protein-Protein Interactions . Mol. Cell. Biol. 13:1993;6336-6345.
32. Lutterbach B., Westendorf J.J., Linggi B., Patten A., Moniwa M., Davie J.R., Huynh K.D., Bardwell V.J., Lavinsky R.M., Rosenfeld M.G., Glass C., Seto E., Hiebert S.W. ETO, a Target of t(8;21) in Acute Leukemia, Interacts with the N-CoR and mSin3 Corepressors. Mol. Cell. Biol. 18:1998;7176-7184.
33. Amann J.M., Nip J., Strom D.K., Lutterbach B., Harada H., Lenny N., Downing J.R., Meyers S., Hiebert S.W. ETO, a Target of t(8;21) in Acute Leukemia, Makes Distinct Contacts with Multiple Histone Deacetylases and Binds mSin3A through its Oligomerization Domain. Mol. Cell. Biol. 21:2001;6470-6483.
34. Kadosh D., Struhl K. Targeted Recruitment of the Sin3-Rpd3 Histone Deacetylase Complex Generates a Highly Localized Domain of Repressed Chromatin in Vivo. Mol. Cell. Biol. 18:1998;5121-5127.
35. Rundlett S.E., Carmen A.A., Suka N., Turner B.M., Grunstein M. Transcriptional Repression by UME6 Involves Deacetylation of Lysine 5 of Histone H4 by RPD3. Nature. 392:1998;831-835.
36. Yang W.M., Yao Y.L., Sun J.M., Davie J.R., Seto E. Isolation and Characterization of cDNAs Corresponding to an Additional Member of the Human Histone Deacetylase Gene Family. J. Biol. Chem. 272:1997;28001-28007.
37. Emiliani S., Fischle W., Van Lint C., Al-Abed Y., Verdin E. Characterization of a Human RPD3 Ortholog, HDAC3. Proc. Natl. Acad. Sci. U.S.A. 95:1998;2795-2800.
38. Dangond F., Hafler D.A., Tong J.K., Randall J., Kojima R., Utku N., Gullans S.R. Differential Display Cloning of a Novel Human Histone Deacetylase (HDAC3) cDNA from PHA-Activated Immune Cells. Biochem. Biophys. Res. Commun. 242:1998;648-652.
39. Taunton J., Hassig C.A., Schreiber S.L. A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p [see comments]. Science. 272:1996;408-411.
40. Nakajima H., Kim Y.B., Terano H., Yoshida M., Horinouchi S. FR901228, a Potent Antitumor Antibiotic, is a Novel Histone Deacetylase Inhibitor. Exp. Cell Res. 241:1998;126-133.
41. Duprez E., Ruchaud S., Houge G., Martin-Thouvenin V., Valensi F., Kastner P., Berger R., Lanotte M. A Retinoid Acid "Resistant" t(15;17) Acute Promyelocytic Leukemia Cell Line Isolation, Morphological, Immunological, and Molecular Features . Leukemia. 6:1992;1281-1287.
42. Lanotte M., Martin-Thouvenin V., Najman S., Balerini P., Valensi F., Berger R. NB4, a Maturation Inducible Cell Line with t(15;17) Marker Isolated from a Human Acute Promyelocytic Leukemia (M3). Blood. 77:1991;1080-1086.
43. Schonberger J., Bauer J., Spruss T., Weber G., Chahoud I., Eilles C., Grimm D. Establishment and Characterization of the Follicular Thyroid Carcinoma Cell Line ML-1. J. Mol. Med. 78:2000;102-110.
44. Tsuchiya S., Yamabe M., Yamaguchi Y., Kobayashi Y., Konno T., Tada K. Establishment and Characterization of a Human Acute Monocytic Leukemia Cell Line (THP-1). Int. J. Cancer. 26:1980;171-176.
45. Tsuchiya S., Kobayashi Y., Goto Y., Okumura H., Nakae S., Konno T., Tada K. Induction of Maturation in Cultured Human Monocytic Leukemia Cells by a Phorbol Diester. Cancer Res. 42:1982;1530-1536.
46. Blaheta R.A., Cinatl J. Jr. Anti-Tumor Mechanisms of Valproate A Novel Role for an Old Drug . Med. Res. Rev. 22:2002;492-511.
47. Gottlicher M., Minucci S., Zhu P., Kramer O.H., Schimpf A., Giavara S., Sleeman J.P., Lo Coco F., Nervi C., Pelicci P.G., Heinzel T. Valproic Acid Defines a Novel Class of HDAC Inhibitors Inducing Differentiation of Transformed Cells. EMBO J. 20:2001;6969-6978.